C olonic diverticula are common in the United States. After the age of 60, more than 50% of individuals in the Unites States have colonic diverticulosis. 1, 2 Although colonic diverticulosis can be complicated by the overt inflammation of acute diverticulitis, there is some thought that colonic diverticulosis is associated with low-grade mucosal inflammation. 3 Moreover, this low-grade diverticular inflammation is believed to contribute to chronic gastrointestinal symptoms. 3 The term symptomatic uncomplicated diverticular disease (SUDD) has been applied to chronic gastrointestinal symptoms attributed to colonic diverticulosis in the absence of overt inflammation. 3 Despite the growing amount of literature associating colonic diverticulosis with low-grade mucosal inflammation and SUDD, the evidence for these associations is poor. A single pilot study found that colonic diverticulosis was associated with an increase in colonic macrophages compared with controls. 4 This study was limited to bivariate comparisons that did not control for confounding variables. The evidence for chronic gastrointestinal symptoms attributed to colonic diverticulosis in Western populations is limited. A population-based study found an association between diverticulosis and diarrhea-predominant irritable bowel syndrome, but only in patients older than age 60. 5 Another study found an association, however, diverticulosis status was abstracted from charts. 6 The evidence that low-grade diverticular inflammation is associated with chronic gastrointestinal symptoms is very low quality and includes a case series 7 and case-control studies with inappropriate controls. 4, 8 Determining whether colonic diverticulosis is associated with chronic mucosal inflammation and chronic gastrointestinal symptoms has clinical implications. The chronic inflammation argument is used as a rationale for treating patients with SUDD with mesalamine. 9 To assess whether colonic diverticula are associated with markers of colonic mucosal inflammation, we conducted a prospective study of patients undergoing a complete screening colonoscopy that included mucosal biopsies. We also examined whether colonic diverticula are associated with chronic gastrointestinal symptoms and explored whether markers of mucosal inflammation were increased among participants with chronic gastrointestinal symptoms. To focus on colonic diverticulosis, we excluded any individual with a history of diverticulitis or with overt diverticular inflammation.
Methods

Study Design
Data for this analysis came from a prospective study to assess risk factors for colonic diverticulosis (National Institutes of Health R01DK094738). The study recruited outpatients undergoing a first-time screening colonoscopy between 2013 and 2015 at the University of North Carolina Hospital in Chapel Hill, North Carolina. The study included patients age 30 years and older with at least a satisfactory preparation for colonoscopy and a complete examination to the cecum. The study excluded any patient with a prior colonoscopy, familial polyposis syndrome (defined as >100 polyps or positive for a familial adenomatous polyposis gene test), evidence of colitis, previous colon resection, previous colon cancer or adenomas, or indication other than screening. Informed consent was obtained from all participants. For this analysis, we excluded patients with a history of diverticulitis (n ¼ 1) or overt diverticular inflammation (n ¼ 4). The University of North Carolina School of Medicine Institutional Review Board approved this study.
Participant Interviews
Each participant completed a detailed telephone interview before the colonoscopy. The interview captured diet, physical activity, tobacco and alcohol use, nonaspirin nonsteroidal anti-inflammatory drug use, aspirin use, bowel habits, and gastrointestinal symptoms. Dietary intake was collected using a 124-item food frequency questionnaire 10 and covered a 12-month period to avoid seasonal variation. Physical activity was assessed using a validated instrument and was expressed as metabolic equivalents in minutes. 11 Race and bowel movement frequency were self-reported. Participants identified the stool form (using the Bristol Stool Scale) they had most of the time. Gastrointestinal symptoms were assessed using Rome III diagnostic criteria questions for irritable bowel syndrome. Chronic abdominal pain was defined as pain or discomfort at least 2 to 3 days a month for at least 6 months.
Colonoscopy and Biopsy
A research assistant measured the participant's height and weight the day of the colonoscopy. During the colonoscopy, the gastroenterologist assessed the colon for diverticula either on insertion or withdrawal. A research assistant was present during the entire examination to document the procedure on a standard data collection form. The gastroenterologist counted the number of diverticula in the colon by segment: cecum, ascending, hepatic flexure, transverse, splenic flexure, descending, and sigmoid colon and reported the findings to the research assistant. Biopsy specimens were taken from normal-appearing mucosa in the midsigmoid in cases and controls for assessment of inflammatory markers. The biopsy specimens (diameter, approximately 3-4 mm) were obtained using standard (8-mm wing) disposable, fenestrated, colonoscopy forceps (Olympus, Center Valley, PA). Laboratory personnel were blinded to clinical information and the diverticulosis status of the subjects.
Intraepithelial Lymphocytes
To evaluate the role of the mucosal immune system in the etiology of diverticulosis, we assessed immune markers and cytokine levels that have been implicated in inflammatory bowel disease and irritable bowel syndrome. We evaluated the following immune markers: CD4, CD8, CD57, and mast cell tryptase. Mouse monoclonal antibodies against human CD4 (NCL-L-CD4-368), CD8 (CD8-4B11-L-CE-S), and CD57 (NCL-NK1) were purchased from Leica Microsystems, Inc (Norwell, MA). Mouse monoclonal anti-human mast cell tryptase (M7052) was purchased from Dako (Carpinteria, CA).
Immunohistochemistry was performed using the Bond fully automated slide staining system (Leica Microsystems, Inc). Tissue sections were deparaffinized in Bond dewax solution (AR9222) and hydrated in Bond wash solution (AR9590). Heat-induced antigen retrieval was performed for 30 minutes at 100 C in Bond-Epitope Retrieval solution 1, pH 6.0 (AR9961; CD4, CD57, and mast cell tryptase) or for 20 minutes in Bond-Epitope Retrieval solution 2, pH 9.0, (AR9640; CD8). Slides were incubated in anti-CD4 or anti-CD8 for 30 minutes at a dilution of 1:200. Incubation in anti-CD57 was performed for 1 hour at a dilution of 1:100, and mast cell tryptase was used at a dilution of 1:3000 with an incubation time of 30 minutes. Detection of all antibodies was performed using the Bond Polymer Refine Detection System (DS9800). Stained slides were dehydrated and cover slipped. Positive and negative controls (no primary antibody) were included for each antibody.
Immunohistochemistry stained sections were imaged digitally (objective, Â20) using the Aperio ScanScope XT (Aperio Technologies, Vista, CA). Analysis of biomarkers was performed using Definiens Tissue Studio software (version 3.6.1; Munich, Germany) with the Composer_Nuclei_and_Simulated_Cells algorithm. The algorithm was trained to recognize cells digitally from the stromal compartment of the colon tissue samples, greatly reducing the number of epithelial cells included in the analysis. The percentage of cells with strong (þ3), medium (þ2), and weak (þ1) positive 3,3 0 -diaminobenzidine tetrahydrochloride signal was used to compare biomarker levels among tissue samples. The H score was calculated for each immune marker. The H score is a composite score that is based on the intensity of staining. The stained cells are counted and then multiplied by a constant based on the intensity of the stain (eg, most intensely stained cells are multiplied by 3). The H-score is computed as follows:
The H score is a continuous variable that ranges from 0 to 300.
We assessed messenger RNA (mRNA) expression levels of interleukin (IL)6, IL10, and tumor necrosis factor a (TNF-a) by quantitative reverse-transcriptase polymerase chain reaction using an established protocol. 12 Briefly, RNA was extracted from mucosal biopsy specimens stored in RNAlater using the RNEasy Mini Kit (Qiagen, Valencia, CA). RNA was quantified by Nanodrop spectrophotometry (ThermoScientific, Wilmington, DE) and the quality was assessed on the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). To ensure that the RNA was free of DNA contamination, we performed DNase digestion using RQ1 RNase Free DNase (Promega, Madison, WI) following the manufacturer's protocol. One microgram of RNA was reverse-transcribed to complementary DNA using Invitrogen cloned AMV (Invitrogen, Carlsbad, CA). Quantitative reverse-transcriptase polymerase chain reaction was performed in duplicate using SYBR Green (BioRad, Hercules, CA) and RT2 profiler (Qiagen) ready-to-use optimized primer sets specific for each gene. The expression of each inflammatory cytokine was evaluated relative to hydroxymethylbilane synthase, which served as a housekeeping gene.
Statistical Analysis
Means and SDs were calculated for continuous variables, medians were calculated for skewed distributions of continuous variables, and proportions were calculated for categoric data. For analysis in the models, the immune markers and mRNA expression levels were converted into categories (quartiles). The 10% change-in estimate approach was used to identify confounding variables. 13 To assess the association between colonic diverticula and markers of mucosal inflammation or gastrointestinal symptoms, proportional odds models 14 were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). The models were adjusted for age, sex, and body mass index. We performed analyses with all diverticulosis cases and cases stratified by number of diverticula. All tests of significance were 2-tailed and P values less than .05 were considered significant. The analysis was performed using SAS 9.4 (SAS, Cary, NC).
Results
Our analysis included 619 participants. Among our participants, 255 (41%) had 1 or more colonic diverticula. Participants with colonic diverticula were more likely to be older, male, and overweight or obese than those without diverticula (Table 1) . Among those with colonic diverticula, 28% had 1 to 3 diverticula, 36% had 4 to 10 diverticula, and 36% had 10 or more diverticula. Among those with colonic diverticula, 61% had only distal diverticula, 29% had distal and proximal diverticula, and 7% had only proximal diverticula.
Colonic Diverticulosis and Mucosal Inflammation
After adjusting for age, sex, and body mass index, there was no association between all cases with diverticulosis and gene expression levels of TNF-a (OR, 0.85; 95% CI, 0.63-1.16) and no association with CD4 (OR, 1.18; 95% CI, 0.87-1.60), CD8 (OR, 0.97; 95% CI, 0.71-1.32), or CD57 (OR, 0.80; 95% CI, 0.59-1.09). Furthermore, there was no association with mast cell tryptase (OR, 1.02; 95% CI, 0.75-1.39). There was a reduced likelihood of mucosal concentrations of IL6 (OR, 0.58; 95% CI, 0.41-0.83) and IL10 (OR, 0.67; 95% CI, 0.49-0.91) ( Table 2) .
Compared with controls, individuals with 1 to 3 colonic diverticula had a reduced mRNA gene expression of IL6 (OR, 0.59; 95% CI, 0.36-0.96) and TNF-a (OR, 0.55; 95% CI, 0.34-0.90). There was a reduced likelihood of mucosal concentrations of the anti-inflammatory cytokine IL10 (OR, 0.50; 95% CI, 0.31-0.82) ( Table 2) . There was no association between a greater burden of colonic diverticula and cytokine gene expression or immune cells ( Table 2 ). The median cytokine expression levels and immunohistochemistry markers by casecontrol status are shown in Supplementary Table 1 .
Because gross inflammation (diverticulitis) is more common in the sigmoid colon, we conducted an analysis stratified by the location of colonic diverticula. Individuals with only distal diverticula compared with no colonic diverticula had a reduced likelihood of IL6 (OR, 0.53; 95% CI, 0.35-0.81) ( Table 3 ). There were no other associations with distal diverticula. Individuals with pandiverticula had a reduced likelihood of CD57 (OR, 0.59; 95% CI, 0.36-0.94). Individuals with only proximal diverticula had a reduced likelihood of CD8 cell density (OR, 0.36; 95% CI, 0.14-0.93) and an increased likelihood of a CD4/CD8 ratio (OR, 4.52; 95% CI, 1.24-16.51).
Colonic Diverticulosis and Gastrointestinal Symptoms
Our analysis included 448 participants who completed the symptom interview. Of these, 12% met the Rome III diagnostic criteria for irritable bowel syndrome and 14% reported chronic abdominal pain (pain or discomfort at least 2-3 days a month for at least 6 months). When examining the extremes of bowel movement frequency, 2.4% had 2 or fewer bowel movements per week, and 0.9% had 22 or more bowel movements per week. Regarding bowel consistency, 11% reported types 1 and 2 Bristol Stool type (hard lumps) and 8% reported types 6 and 7 (watery, mushy) most of the time. Participants with irritable bowel syndrome were younger, more likely to be female, and overweight or obese than those without irritable bowel syndrome (Supplementary Table 2) .
Adjusting for age, sex, and body mass index, individuals with 1 or more colonic diverticula had no significant association with irritable bowel syndrome (OR, 0.53; 95% CI, 0.26-1.05) (Table 4) . Moreover, there was no association between the number of colonic diverticula and the odds of irritable bowel syndrome (Table 4) . Similarly, there was no association between having colonic diverticula and chronic abdominal pain (OR, 0.68; 95% CI, 0.38-1.23). Compared with Bristol Stool types 3, 4, and 5, there was no association between colonic diverticulosis and stool types 1 and 2 (OR, 1.03; 95% CI, 0.52-2.05) or types 6 and 7 (OR, 1.20; 95% CI, 0.55-2.61).
Colonic Diverticula, Gastrointestinal Symptoms, and Mucosal Inflammation
We identified 42 participants who met the criteria for Rome III irritable bowel syndrome and had mucosal biopsies. Among these participants, 11 had colonic diverticulosis and 31 did not have diverticulosis. In bivariate comparisons, there were no differences in mucosal inflammatory markers, IL6, IL10, TNF, CD4, CD8, or mast cell tryptase (Table 5) . Likewise, we identified 63 participants with chronic abdominal pain. Among these participants, 22 had colonic diverticulosis and 41 did not have diverticulosis. In bivariate comparisons, there were no differences in the mucosal inflammatory markers, IL6, IL10, TNF, CD4, CD8, or mast cell tryptase (Table 5) .
Discussion
In this large colonoscopy-based study of individuals without a history of diverticulitis or overt peridiverticular inflammation, we found that colonic diverticulosis was not associated with mucosal inflammation. We also found no association between colonic diverticulosis and chronic gastrointestinal symptoms. We explored whether markers of mucosal inflammation were increased among participants with chronic gastrointestinal symptoms and diverticulosis compared with those without diverticulosis. There was no evidence for mucosal inflammation in individuals with diverticulosis and chronic gastrointestinal symptoms, so-called SUDD.
The evidence that colonic diverticulosis without overt inflammation in an asymptomatic population without a history of diverticular disease is associated with lowgrade mucosal inflammation is limited. A study from Italy assessed whether colonic mucosa from asymptomatic patients with diverticula was associated with markers of inflammation compared with those without diverticula. 4 Similar to our work, there was no difference in T-cell and mast cell counts between groups. Colonic macrophages were increased significantly in patients with colonic diverticula compared with those without diverticula. Notably, this was a pilot study of 30 participants and was limited to bivariate comparisons that did not control for confounding variables. In Western countries, there is an increasing incidence of chronic inflammatory diseases of the gastrointestinal tract in the absence of overt infection. 15 To evaluate a potential role for the mucosal immune system in the etiology of diverticulosis, we assessed immune markers and cytokine levels, which have been implicated in inflammatory bowel disease and irritable bowel syndrome. The inflammatory response in Crohn's disease consists mainly of T cells and macrophages whereas the inflammation of ulcerative colitis is restricted to the mucosa with predominant infiltration by neutrophils. 15 There is some evidence for an imbalance of mucosal proinflammatory TNF-a and anti-inflammatory IL10 in irritable bowel syndrome, a condition previously considered a motility disorder. 16 Increased mucosal mast cell infiltration also has been reported in several studies of patients with irritable bowel syndrome. 17 Despite assessing an array of immune markers and cytokine levels, our work found no evidence that colonic diverticulosis is associated with mucosal inflammation, which suggests that chronic mucosal inflammation is not likely to be responsible for the development of diverticulosis.
SUDD has been defined as a subtype of diverticular disease in which there are persistent abdominal symptoms in the absence of macroscopically overt colitis or diverticulitis. 18, 19 Once colonic diverticula form, there is the potential for numerous complications. The most common diverticular complication is acute diverticulitis. Beyond diverticulitis, there is growing evidence for a spectrum of chronic diverticular-related bowel disorders. Many of these disorders remain ill-defined, however, each likely has a separate pathophysiology. SUDD should not be confused with chronic or smoldering diverticulitis, segmental colitis associated with diverticular disease, or the chronic gastrointestinal symptoms experienced after an episode of diverticulitis.
Whether SUDD is a valid condition independent of irritable bowel syndrome is controversial. There are no consistent definitions of SUDD in the literature. Some investigators have defined SUDD as abdominal pain and changes in bowel habits attributed to diverticula in the absence of alternate etiologies. 5, 20, 21 Although other investigators have defined SUDD as abdominal pain in patients with diverticulosis in the absence of any complications (stenosis, abscess, and fistulas) and in which the presence of abdominal pain is noted in the left lower quadrant lasting for more than 24 hours. 18, 22, 23 Because of the possible overlap between IBS and SUDD, clinical criteria have been developed to differentiate the 2 entities. 22 Patients with SUDD are older than IBS patients, lack the female predominance of IBS, and have prolonged episodes of pain. 22 The pain is thought to arise from muscular contractions. Based on 24-hour manometry studies, patients with diverticulosis had a significant increase in regular patterns of phasic pressure activity compared with controls, and 30% reported cramping and lower abdominal pain during colonic contractions. 24 The study was based on small numbers (12 patients) and painful episodes and, although associated with contractions, lasted for 5 to 10 minutes.
The evidence for colonic diverticulosis and associated gastrointestinal symptoms is limited. A populationbased, colonoscopy-based study from Sweden found that participants with diverticulosis were more likely to report loose stools (OR, 1.88; 95% CI, 1.20-2.96) and high stool frequency (OR, 2.02; 95% CI, 1.11-3.65). There was no significant association with abdominal pain, irritable bowel syndrome, or irritable bowel syndrome subtypes. In analyses limited to individuals older than age 60, participants with diverticulosis had an increased risk of abdominal pain (OR, 2.10; 95% CI, 1.01-4.37) and diarrhea-predominant irritable bowel syndrome (OR, 9.55; 95% CI, 1.08-84.1) compared with participants without diverticulosis. 5 In this study, colonic diverticula were not assessed in a standard manner and the gastroenterologist who performed the colonoscopy many times also performed the preprocedure medical examination. 25 If the gastroenterologist believed that a patient's gastrointestinal symptoms were associated with colonic diverticulosis, they may have been biased to overdetect and over-report colonic diverticula in patients with symptoms. The prevalence of colonic diverticulosis was substantially lower in this Swedish study (10%-25% of participants aged 50-59 years) compared with the prevalence of diverticulosis in US populations (33%-40% of adults aged 50-59 years). 1, 2 This may reflect a difference in the prevalence of diverticulosis in these 2 countries or under-reporting in the Swedish study.
Diverticulosis also was associated with irritable bowel syndrome in a study that used a survey and chart review. 6 Again, colonic diverticulosis was not assessed in a standard manner and there was the same potential for bias as in the Swedish study. In a study design similar to our own, distal diverticulosis was associated with irritable bowel syndrome in a study from Japan. 26 In contrast with prior work, we found no association between colonic diverticulosis and chronic abdominal pain or irritable bowel syndrome.
The evidence that low-grade diverticular inflammation is associated with chronic gastrointestinal symptoms is of very low quality. The most commonly cited evidence is a case series of 17 patients with diverticulosis and gastrointestinal symptoms, 94% had histopathology findings of chronic nonspecific inflammation. 7 This case series was published in abstract form only, did not include controls, and included patients with a spectrum of gastrointestinal symptoms (diarrhea, constipation, rectal bleeding, weight loss, and bloating). A small Italian study found no evidence for mucosal inflammation when comparing patients with SUDD and asymptomatic controls. 8 A pilot study found that patients with SUDD compared with asymptomatic controls without diverticula had higher levels of mucosal mast cells and macrophage counts. 4 Notably, the controls in both studies did not have colonic diverticula. Because there is evidence for mucosal inflammation in irritable bowel syndrome, these were not appropriate controls. 16 We explored whether markers of mucosal inflammation were increased among participants with chronic gastrointestinal symptoms who had diverticulosis compared with participants with symptoms who did not have diverticulosis. Because there is evidence that irritable bowel syndrome is associated with mucosal inflammation, we did not compare patients with and without irritable bowel syndrome. Instead, we were interested in whether there might be a subtype of individuals with irritable bowel syndrome (or chronic abdominal pain) with low-grade inflammation secondary to colonic diverticula. We found no evidence for mucosal inflammation in individuals with diverticulosis and the symptoms of irritable bowel syndrome or chronic abdominal pain. This finding has clinical implications. Based on the theory that SUDD is the result of chronic peridiverticular mucosal inflammation, some investigators recommend treatment with mesalamine. 9 Our findings strongly question the rationale for treating SUDD with mesalamine.
Our work had notable strengths. This was a prospective study designed to study factors associated with colonic diverticula. Every participant had a complete colonoscopy and assessment for diverticula. Colon biopsy specimens were obtained in a uniform manner. Gastrointestinal symptoms were assessed using Rome criteria. Confounding variables were measured and accounted for in our analyses. The panel of inflammatory markers allowed us to assess both local inflammation and immune activation in the colonic mucosa. Our work also had limitations. Because we included only patients presenting for a screening colonoscopy, we had a small number of participants with IBS in our sample. Moreover, we did not have a measure of IBS severity or IBS subtypes. Although we studied several immune markers and cytokines, there are other potential markers that may be associated with chronic inflammation. Multi-analyte profiling could be used to assess an array of cytokines, and markers for macrophages (CD68), global T cells (CD3), and B cells (CD19). Whether there is utility in further studies given our negative results is debatable.
In summary, we found no evidence that colonic diverticula are associated with mucosal inflammation or chronic gastrointestinal symptoms. Our data challenge the concept that colonic diverticulosis is a state of chronic inflammation and suggest that chronic mucosal 
